Image

Global Medication-Assisted Treatment (MAT) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 727
  • No of Figures: 82
  • Pharmaceutical
  • Published Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 727
  • No of Figures: 82

Global Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals Specialty Centres, Homecare and Others), Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others), Industry Trends and Forecast to 2029

Medication-Assisted Treatment (MAT) Market

Market Analysis and Insights

The Food and Drug Administration (FDA) approved three drugs for clinical use which are buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and by Substance Abuse and Mental Health Services Administration (SAMHSA), naloxone is one of many medications considered essential to a functioning health care system.

Medication-Assisted Treatment (MAT) Market

Medication-Assisted Treatment (MAT) Market

The global medication-assisted treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the medication-assisted (MAT) treatment market will grow at a CAGR of 9.4% during the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others)

Countries Covered

By Country (U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa)

Market Players Covered

Indivior PLC, Orexo US Inc (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Accord Healthcare, VistaPharm, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. among others.

 

 

Market Definition

Medication-assisted treatment (MAT), involves the use of medications, combined with counselling and behavioural therapies, to provide a complete patient approach for treating substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. The aim of MAT is proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and grow in pregnancy outcomes among women.

Global Medication-Assisted (MAT) Treatment Market Dynamics

Drivers

  • The Rise In Incidence Of Alcohol Use Disorder and Opioid Use Disorders

Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, and alcohol addiction.

For instance,

  • In 2022, the data by World Health Organization (WHO) European Region stated that alcohol disorder causes 1 million deaths annually

Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.

  • Use Of Reimbursement For Medication-Assisted Treatment (MAT)

Reimbursement may be available for medication-assisted treatment even if the medication does not have a valid status.

For instance,

  • In February 2021, The American College of Emergency Physicians (ACEP) had developed the Reimbursement & Coding FAQs and Pearls for informational purposes on medication-assisted treatment

While, if the medication does not have preferred status, the prescriber must obtain permission from the member's pharmacy benefit plan.

Medication-Assisted Treatment (MAT) Market

Opportunities

  • Rise In Healthcare Expenditure

Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.

For instance,

  • In February 2021, according to Health Care Price Index (HCPI), the total U.S. healthcare budget had increased by 3.4%. The increase in growth states the federal government spending decreased significantly in the previous year from USD 287,000 million in 2020 to USD 170,000 million in 2021

Strategic Initiative By Market Players

The demand for medication-assisted treatment has increased in the U.S. and Europe due to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.

For instance,

  • In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations

These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.

Restraints/Challenges

  • Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT)

Medication-assisted treatment (MAT) involves using medications collated with counselling and behavioural therapies to provide a "whole-patient" approach as part of the comprehensive treatment strategy. MAT has been shown to be most effective for treating alcohol and opioid use disorders. However, certain side effects have been reported

For instance,

  • Methadone and buprenorphine, the generic medications, are chemically similar to opioids, so their side effects can be similar too. These may include constipation, drowsiness, and dizziness. Some people may experience more severe side effects

Therefore, the present high cost is expected to show a descending trend.

  • The Lack of Skilled Professionals, Required for Medication-Assisted Treatment

The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.

For instance,

  • In February 2021, according to NCBI, cultural barriers may include staff resistance to the use of medication-assisted treatment (MAT), a lack of perceived effectiveness of MAT, and a lack of knowledge about how to implement MAT within their treatment setting. Furthermore, little is known about how patient characteristics may be related to organizational decisions regarding the implementation of MAT

The Medication-assisted (MAT) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

Covid-19 Impact on the Medication-Assisted (MAT) Treatment Market

During the pandemic, medication-assisted treatment remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during Covid-19 Medication for opioid use disorder (MOUD) services are key to addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.

Recent Development

  • In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations

Global Medication-Assisted Treatment (MAT) Market Scope

The medication-assisted (MAT) treatment market is segmented on the basis of eight segments: type, products, drug type, dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Medication
  • Therapy

On the basis of type, the global medication-assisted (MAT) treatment market is segmented into medication and therapy.

Products

  • Buprenorphine and Naloxone
  • Naltrexone
  • Buprenorphine
  • Methadone
  • Naloxone
  • Disulfiram
  • Acamprosate

On the basis of products, the global medication-assisted (MAT) treatment market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate.

Drug Type

  • Generics
  • Branded

On the basis of drug type, the global medication-assisted (MAT) treatment market is segmented into generics and branded.

Dosage Form

  • Immediate Release
  • Extended Release

On the basis of dosage form, the global medication-assisted (MAT) treatment market is segmented into immediate release and extended release.

Route of Administration

  • Oral
  • Parenteral
  • Others

On the basis of route of administration, the global medication-assisted (MAT) treatment market is segmented into oral, parenteral and others.

Population Type

  • Teenage
  • Adults

On the basis of population type, the global medication-assisted (MAT) treatment market is segmented into adults and teenage.

End User

  • Rehabilitation Clinics
  • Hospitals
  • Speciality Centers
  • Homecare
  • Others

On the basis of end user, the global medication-assisted (MAT) treatment market is segmented into rehabilitation clinics, hospitals, speciality centers, homecare and others.

Distribution Channel

  • Hospital Pharmacy
  • Direct Tender
  • Retail Pharmacy
  • Online Pharmacy
  •  Others

Medication-Assisted Treatment (MAT) Market

On the basis of distribution channel, the global medication-assisted (MAT) treatment market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others

Medication-Assisted (MAT) Treatment Market Regional Analysis/Insights

The global medication-assisted (MAT) treatment market is analysed, and market size insights and trends are provided by regions, product type, application, workflow, end user and distribution channel. As referenced above.

The countries covered in the medication-assisted (MAT) treatment market report are the U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland, and Rest of Europe., China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, and the Rest of Middle East and Africa.

North America is expected to dominate the market due to a rise in the incidence of substance use disorders, ongoing clinical trials, and pharmaceutical companies.

Medication-Assisted Treatment (MAT) Market

The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Medication-Assisted (MAT) Treatment Market Share Analysis

The global medication-assisted (MAT) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the medication-assisted (MAT) treatment market.

Some of the major players operating in the medication-assisted (MAT) treatment market are Indivior PLC, Orexo US Inc. (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Accord Healthcare, VistaPharm, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. among others.


SKU-
Why Choose Us


Frequently Asked Questions

The Medication-Assisted Treatment (MAT) Market will grow at a CAGR of 9.4% by 2029.
The Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT), and The Lack of Skilled Professionals, Required for Medication-Assisted Treatment are poised to restrict the market growth.
The major players operating in the Medication-Assisted Treatment (MAT) Market are Indivior PLC, Orexo US Inc (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Accord Healthcare, VistaPharm, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. among others.
The major countries covered in the Medication-Assisted Treatment (MAT) Market are U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa.